Wire · opportunities
CVS settles with FTC, agrees to count TrumpRx drug purchases towards insurance
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 16 July 2026 · Fusion42 review
CVS Caremark settles with the FTC, agreeing to count TrumpRx purchases toward insurance deductibles, eliminate rebate-based pricing models, and cap insulin out-of-pocket costs at $25/month. The settlement mirrors earlier enforcement against Cigna and Express Scripts, and regulators estimate it will save billions on drug prices.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you're building any alternative to pharmacy benefit managers—discount networks, direct-to-consumer pharma, or employer drug-purchasing platforms—the FTC just handed you your pitch: rebate models are now toxic, and CVS has been forced to build what you're selling. Employers and insurers are watching this settlement; they now have permission to switch.
◆ Coverage
1 source · 16 Jul 2026
◆ Related on Wire
◆ Topics